AIMS/HYPOTHESES: Chronic hyperglycaemia increases dipeptidyl peptidase IV (DPP-IV) activity in endothelial cells in vitro. The present study was designed to assess the effect of high glucose on circulating DPP-IV activity in patients with type 1 and type 2 diabetes. METHODS: Plasma DPP-IV activity was measured in 29 patients with type 1 diabetes and 29 age-, sex- and BMI-matched control subjects. We also assessed DPP-IV activity in 31 type 2 diabetic patients with HbA1c > 8.5% and in plasma from matched groups of 31 newly diagnosed diabetic subjects with HbA1c < 7.5%, 31 subjects with IGT and 62 subjects with NGT. In a further sample of 66 type 2 diabetic patients, a longitudinal study was also performed to evaluate variations in DPP-IV activity and HbA1c over 3 months. RESULTS: DPP-IV activity in type 1 diabetic patients was not significantly different from that in control subjects; however, a significant correlation between DPP-IV and HbA1c was observed in diabetic subjects (r = 0.47; p < 0.01). Type 2 diabetic patients with HbA1c > 8.5% showed significantly (p < 0.05) higher DPP-IV activity (mean+/-SD 27.7+/-7.1 U/l) than newly diagnosed diabetic patients and subjects with IGT (22.1+/-6.0 and 18.8+/-8.8 U/l, respectively). Variations in DPP-IV activity over 3 months in type 2 diabetic patients showed a significant positive correlation with variations in HbA1c (r = 0.26; p < 0.05). CONCLUSIONS/ INTERPRETATION: Chronic hyperglycaemia induces a significant increase in DPP-IV activity in type 1 and type 2 diabetes. This phenomenon could contribute to the reduction in circulating active glucagon-like peptide-1 and to the consequent postprandial hyperglycaemia in type 2 diabetic patients with poor metabolic control.
AIMS/HYPOTHESES: Chronic hyperglycaemia increases dipeptidyl peptidase IV (DPP-IV) activity in endothelial cells in vitro. The present study was designed to assess the effect of high glucose on circulating DPP-IV activity in patients with type 1 and type 2 diabetes. METHODS: Plasma DPP-IV activity was measured in 29 patients with type 1 diabetes and 29 age-, sex- and BMI-matched control subjects. We also assessed DPP-IV activity in 31 type 2 diabeticpatients with HbA1c > 8.5% and in plasma from matched groups of 31 newly diagnosed diabetic subjects with HbA1c < 7.5%, 31 subjects with IGT and 62 subjects with NGT. In a further sample of 66 type 2 diabeticpatients, a longitudinal study was also performed to evaluate variations in DPP-IV activity and HbA1c over 3 months. RESULTS:DPP-IV activity in type 1 diabeticpatients was not significantly different from that in control subjects; however, a significant correlation between DPP-IV and HbA1c was observed in diabetic subjects (r = 0.47; p < 0.01). Type 2 diabeticpatients with HbA1c > 8.5% showed significantly (p < 0.05) higher DPP-IV activity (mean+/-SD 27.7+/-7.1 U/l) than newly diagnosed diabeticpatients and subjects with IGT (22.1+/-6.0 and 18.8+/-8.8 U/l, respectively). Variations in DPP-IV activity over 3 months in type 2 diabeticpatients showed a significant positive correlation with variations in HbA1c (r = 0.26; p < 0.05). CONCLUSIONS/ INTERPRETATION:Chronic hyperglycaemia induces a significant increase in DPP-IV activity in type 1 and type 2 diabetes. This phenomenon could contribute to the reduction in circulating active glucagon-like peptide-1 and to the consequent postprandial hyperglycaemia in type 2 diabeticpatients with poor metabolic control.
Authors: J P Gutzwiller; B Göke; J Drewe; P Hildebrand; S Ketterer; D Handschin; R Winterhalder; D Conen; C Beglinger Journal: Gut Date: 1999-01 Impact factor: 23.059
Authors: E Mannucci; A Ognibene; F Cremasco; G Bardini; A Mencucci; E Pierazzuoli; S Ciani; A Fanelli; G Messeri; C M Rotella Journal: Diabet Med Date: 2000-10 Impact factor: 4.359
Authors: R Lugari; C Dell'Anna; D Ugolotti; A Dei Cas; A L Barilli; R Zandomeneghi; B Marani; M Iotti; A Orlandini; A Gnudi Journal: Horm Metab Res Date: 2000-10 Impact factor: 2.936
Authors: E Mannucci; A Ognibene; F Cremasco; G Bardini; A Mencucci; E Pierazzuoli; S Ciani; G Messeri; C M Rotella Journal: Diabetes Care Date: 2001-03 Impact factor: 19.112
Authors: E Mannucci; A Ognibene; I Sposato; M Brogi; G Gallori; G Bardini; F Cremasco; G Messeri; C M Rotella Journal: Acta Diabetol Date: 2003-12 Impact factor: 4.280
Authors: P J English; A Ashcroft; M Patterson; T M Dovey; J C G Halford; J Harrison; D Eccleston; S R Bloom; M A Ghatei; J P H Wilding Journal: Diabetologia Date: 2006-07-11 Impact factor: 10.122
Authors: E Mannucci; L Pala; M Monami; L Da Vico; G Bardini; I Dicembrini; S Ciani; C Lamanna; N Marchionni; C M Rotella Journal: J Endocrinol Invest Date: 2009-09-11 Impact factor: 4.256
Authors: Gábor Firneisz; Tímea Varga; Gabriella Lengyel; János Fehér; Dóra Ghyczy; Barna Wichmann; László Selmeci; Zsolt Tulassay; Károly Rácz; Anikó Somogyi Journal: PLoS One Date: 2010-08-18 Impact factor: 3.240